CSF3 and Miscarriage: The findings of this meta-analysis indicate that intrauterine administration of G-CSF during the luteal phase and at ovulation can reduce the risk of miscarriage in patients with recurrent miscarriage and increase the live birth rate, highlighting its significant clinical application value in the treatment of recurrent miscarriage.